flavocoxid

flavocoxid

(fla-vo-cox-id) ,

Limbrel

(trade name)

Classification

Therapeutic: nonopioid analgesics
Pharmacologic: flavanoids
Pregnancy Category: UK

Indications

Dietary management of osteoarthritis; considered to be a medical food product.

Action

Anti-inflammatory and analgesic properties related to inhibition of prostaglandin synthesis by inhibiting cyclo-oxygenase (not COX-2 selective) and other mediators of inflammation.

Therapeutic effects

Decreased pain/inflammation associated with osteoarthritis, with improved mobility.

Pharmacokinetics

Absorption: Some intestinal conversion prior to absorption, remainder unknown.
Distribution: Unknown.
Metabolism and Excretion: Mostly metabolized by the liver.
Half-life: Unknown.

Time/action profile (analgesic effect)

ROUTEONSETPEAKDURATION
POwithin 1–2 hrunknown12 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Obstetric / Lactation / Pediatric: Not recommended.
Use Cautiously in: History of GI bleeding.

Adverse Reactions/Side Effects

Cardiovascular

  • ↑ BP
  • ↑ in varicose veins

Gastrointestinal

  • GI upset

Dermatologic

  • psoriasis

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Oral (Adults) 250 mg every 12 hr (up to 250 mg three times daily has been used).

Availability

Capsules: 250 mg

Nursing implications

Nursing assessment

  • Assess pain (note type, location, and intensity), range of motion, degree of swelling, and stiffness in affected joints before and periodically during therapy.

Potential Nursing Diagnoses

Chronic pain (Indications)

Implementation

  • Oral: Administer flavocoxid twice daily.

Patient/Family Teaching

  • Instruct patient to take flavocoxid as directed. Do not increase does without consulting health care professional.

Evaluation/Desired Outcomes

  • Decrease in pain and stiffness, and improved mobility in patients with osteoarthritis.
Mentioned in ?
References in periodicals archive ?
The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation.
Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages.
A proprietary mixture of flavonoids (baicalin and catechin), known as flavocoxid (Limbrel) was tested against naproxen, a conventional nonsteroidal anti-inflammatory drug for the management of moderate osteoarthritis of the knees.
Irrera et al., "Flavocoxid, a nutraceutical approach to blunt inflammatory conditions," Mediators of Inflammation, vol.
Relevantly, the infiltration of Th[1.sup.+] and Th[17.sup.+] cells in the inflamed area of the brain was reduced by the dual inhibitor of LOX/COX pathway flavocoxid and by montelukast in EAE mice [148,154].
David et al., "Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis," Critical Care, vol.
Flavocoxid is marketed as a medical food for the management of OA.
Now along comes Limbrel, each capsule containing 250 mg of flavocoxid. The product is a proprietary blend of Free-B-Ring flavonoids and flavans from GRAS phytochemical food sources.
Chopra, "Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke," Pharmacology Biochemistry and Behavior, vol.
One such extract with strong supporting human outcome studies, flavocoxid, will be discussed in this article with emphasis on its safety profile and balanced action across a multitude of inflammatory pathways.
Limbrel contains flavocoxid, a proprietary blend of natural ingredients from phytochemical food source materials.